In this national cohort of PM-CRC patients treated with CRS-HIPEC, we found a high incidence of BRAF mutations (24%), and in contrast to two prior reports, we did not see any differences in survival after CRS-HIPEC according to KRAS or BRAF mutational status. This evidence concerns the gene KRAS and colorectal carcinoma.